Approval clears Boehringer to enter oncology space

Share this article:

Boehringer Ingelheim has officially entered the oncology space. The FDA approved the private company's once-daily pill for metastatic non-small cell lung cancer (NSCLC) medication, Gilotrif, on Friday. The FDA gave the first-line oral cancer treatment orphan drug status and priority review.

Gilotrif (afatinib) is for a specific subset of patients: those with NSCLC who have epidermal growth factor receptor (EGFR) mutations. Although 85% of lung cancers are NSCLC, only around 10% of these patients have these specific mutations. The FDA also approved a companion diagnostic to identify this mutation on FridayQiagen's Therascreen EGFR.

The BI/Qiagen approval may be familiar to oncology watchers. That's because in May the FDA not only approved Roche's Tarceva as a first-line treatment for this very same condition, but also approved Roche's biomarker test to help identify patients who will benefit from the EGFR treatment.

Data supporting the FDA's approval of BI's new oncology drug included a clinical trial of 345 patients that showed a progression-free survival rate of 4.2 months longer than patients who received chemotherapy, although there was no statistical difference when it came down to overall survival rates.

The oral tyrosine kinase receptor inhibitor is BI's first marketed cancer med. Also in Phase III are nintedanib, an oral triple angiokinase inhibitor that is also being tested in NSCLC and ovarian cancers.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...